Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03MGL
|
|||
| Former ID |
DNCL001902
|
|||
| Drug Name |
Tafamidis meglumine
|
|||
| Synonyms |
Tafamidis meglumine; Fx-1006A; Fx1006A; Fx 1006A; UNII-ZU7CF08A1A; ZU7CF08A1A; 951395-08-7; CHEBI:79345; Tafamidis meglumine [USAN:INN]; SCHEMBL14783506; CHEMBL2105675; Tafamidis meglumine (JAN/USAN); SB16821; D-Glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate; FT-0700926; D09674; 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid--1-deoxy-1-(methylamino)-D-glucitol (1/1); 1-deoxy-1-(methylazaniumyl)-D-glucitol 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hereditary amyloidosis [ICD-11: 5D00.2; ICD-10: E85.2] | Approved | [1] | |
| Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20; ICD-10: E85.1] | Phase 3 | [2] | ||
| Company |
FoldRx Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H24Cl2N2O8
|
|||
| Canonical SMILES |
CNCC(C(C(C(CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
|
|||
| InChI |
1S/C14H7Cl2NO3.C7H17NO5/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-6H,(H,18,19);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
|
|||
| InChIKey |
DQJDBUPLRMRBAB-WZTVWXICSA-N
|
|||
| CAS Number |
CAS 951395-08-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:79345
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
| REF 2 | ClinicalTrials.gov (NCT01994889) Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.